The AI-native advantage in life sciences

Imagine walking into a clinic one morning and walking out that afternoon with a personalized cure tailored to your exact genetic profile and disease variant. Diagnosis and treatment — all in a matter of hours. This is the future many people envision when they hear "AI in healthcare," but it’s not our reality, — at least not yet. 

Today, the ideal treatment for a patient may already exist but be locked in clinical trials, years away from regulatory approval. The very safeguards designed to protect patients may also keep breakthrough therapies just out of reach.

AI can't deliver instant cures, but it can address unnecessary delays. Bringing a new treatment to market takes many years. COVID vaccines proved faster timelines are possible, and the question now is how to make speed the standard rather than the exception. AI is beginning to answer that, collapsing months of manual regulatory work into days.

Connected data that flows

Regulatory teams sometimes spend days hunting for data misalignments buried in thousands of documents from clinical sites, only to discover a formatting error that had nothing to do with whether the treatment actually works. A single mismatch, such as a dosage formatted differently across documents, can trigger regulatory queries that add months to an approval timeline.

Trial data, published literature, manufacturing records, and safety surveillance must be scientifically defensible and formatted to meet agency requirements. That work takes months because regulatory teams rely on tools built to organize and store documents — not to interpret relationships between data points, identify inconsistencies across thousands of pages, or synthesize information into submission-ready formats. Manual document assembly has crowded out the work that matters most: collaborative scientific dialogue. 

AI is finally changing this with agents that can automate regulatory work at scale. You can deploy these agents across your existing systems without ripping out the infrastructure you've spent years building. And the more you set your agents up for success, the faster you can go.

Many companies approach AI by assembling separate pieces — an AI model from one vendor, a data warehouse from another, security tools from a third. They hire developers to write custom "glue code" to make these disconnected systems talk to each other. That works for simpler applications. It breaks down when AI agents need to move quickly across vast clinical databases, manufacturing systems, and literature repositories while maintaining strict audit controls.

An AI-native platform with built-in governance, security, and audit trails treats data as a ready-to-use product that agents can consume directly, rather than something to first copy and move between systems. The AI layer and data layer work as a unified fabric, so agents can access information in existing systems through standard healthcare protocols, including Fast Healthcare Interoperability Resources (FHIR), Health Level Seven (HL7), and Digital Imaging and Communications in Medicine (DICOM). No data migration required. No glue code to maintain. Agents get direct access to the information they need.

The advantage of an AI-native platform

These changes are already happening – removing manual bottlenecks while maintaining the human judgment and accountability that regulated science requires:

Document generation and first drafting. Research-focused AI tools process large volumes of clinical data, literature, and past submissions to create structured evidence summaries and document outlines. From there, generative AI completes first drafts for regulatory experts to review, edit, and finalize. Within days, teams have a structured submission ready for the next steps.

Compliance and quality control. AI cross-checks thousands of pages against published FDA and EMA guidelines. Predictive analytics identify anomalies and potential regulatory queries before submission. If issues surface, AI agents route them to the appropriate team automatically.

Accelerated response to regulatory queries. When agencies request clarification, AI searches and retrieves relevant information across the full data estate, then drafts initial responses that experts refine. What previously took weeks of document hunting now takes hours of focused expert review, with complete audit trails and timestamped transparency built in.

None of this works unless AI can access both structured data — clinical trial results in databases — and unstructured content like published research papers, and regulatory correspondence. Gemini Enterprise addresses this directly. By unifying the AI and data layers into a single fabric, it gives regulatory agents the access they need to work effectively.

Vertex AI, Google's machine learning platform, and BigQuery, Google's analytics data warehouse, operate together rather than as separate systems. When an AI agent needs to cross-reference clinical outcomes with manufacturing batch records and published literature, it doesn't have to wait for data engineers to build custom pipelines or for IT teams to reconcile security policies across tools from different vendors. The information flows directly to where it's needed, with governance and audit controls built into the platform itself rather than layered on afterward.

The real measure of success

Major pharmaceutical and medical device companies exploring AI for drug discovery are applying the same thinking to regulatory work, where time-to-market pressure is equally acute. Early adopters are automating significant portions of regulatory dossier preparation and seeing measurable reductions in submission timelines.

The shift is as much about focus as it is about speed. When AI agents handle document assembly, cross-checking, and evidence retrieval, experts can apply their scientific judgment to evaluating safety, assessing risk-benefit trade-offs, and making the case for why a treatment should reach patients. 

Agentic AI establishes the foundation for transitioning from static point in time dossiers to a continuous stream of regulatory submissions. By utilizing dynamic insights, regulatory filings can synchronously evolve as new evidence becomes available, updated in almost real-time with emerging research and new post-market surveillance findings. Regulatory review becomes an ongoing real-time scientific exchange with regulators grounded in latest data. Patients get access to treatments based on the strongest possible case, built on evidence as it emerges rather than evidence as it existed months ago. 

When the evidence base strengthens, patients benefit. The partnership with regulators centers on scientific substance rather than document logistics. This reduces the delay between discovery and delivery for patients who are waiting and hoping.